Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: Collaborative Depression Care Management in Treating Depressed Low-income Hispanics With Diabetes [Phase 4]
Phase 4 clinical trial update evaluating collaborative depression care management in depressed low-income Hispanic individuals with diabetes…
-
FDA approval · 2023-11-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for venlafaxine hydrochloride extended-release (Chartwell RX, LLC), reflecting an approved update to…
-
FDA approval · 2023-11-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application for venlafaxine hydrochloride from Granules Pharmaceuticals Inc., authorizing an additional form…
-
FDA approval · 2023-11-20FDA Approved: CITALOPRAM HYDROBROMIDE — Supplemental Application (Glenmark Therapeutics Inc., USA)
FDA approved Glenmark Therapeutics’ supplemental application for Citalopram Hydrobromide as a generic antidepressant. Citalopram hydrobromid…
-
FDA approval · 2023-11-20FDA Approved: FLUOXETINE — Supplemental Application (Endo USA, Inc.)
The FDA approved a supplemental application for fluoxetine submitted by Endo USA, Inc., resulting in regulatory changes to the product's sta…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Measuring Blood Flow in the Brain After Epileptic Activity [Phase 2]
Phase 2 clinical trial update evaluating blood flow measurement in the brain following epileptic activity.
-
FDA approval · 2023-11-15FDA Approved: FLUOXETINE — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for fluoxetine (generic) from Micro Labs Limited under an ANDA.
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Rapid Improvement of Depression of Fluoxetine Combined With ATP [Phase 2]
Phase 2 clinical trial investigating rapid improvement of depression with fluoxetine combined with ATP.
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Effect of Medical Marijuana on Neurocognition and Escalation of Use [NA]
Clinical trial update on the effects of medical marijuana on neurocognition and escalation of use; study completed with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2023-11-14Clinical Trial Update: The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN) [Phase 4]
Phase 4 clinical trial update investigating Negr1's role in neuroplasticity for major depressive disorder and bipolar depression, status cur…
-
CLINICAL_TRIALS withdrawal · 2023-11-14Clinical Trial Update: Anti-suicidal Effects of Buprenorphine In Depressed Individuals [Phase 3]
A Phase 3 trial evaluating buprenorphine for anti-suicidal effects in depressed individuals has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: Ketamine Treatment Effects on Synaptic Plasticity in Depression [Phase 4]
Phase 4 trial examining ketamine's effects on synaptic plasticity in major depressive disorder has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Efficacy and Safety of Sertraline in the Treatment of Maintenance Hemodialysis Patients With Depression [Phase 4]
Phase 4 trial assessing sertraline for efficacy and safety in maintenance hemodialysis patients with depression has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder [Phase 3]
Phase 3 trial comparing Sage-217 plus an antidepressant to placebo plus an antidepressant in adults with major depressive disorder; study co…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk [Phase 2]
Phase 2 pilot trial evaluating depression treatment to reduce diabetes risk has completed with results posted.
-
FDA approval · 2023-11-01FDA Approved: DESVENLAFAXINE — Supplemental Application (Slate Run Pharmaceuticals, LLC)
FDA approved a supplemental application for desvenlafaxine submitted by Slate Run Pharmaceuticals, LLC, updating the regulatory status of th…
-
FDA approval · 2023-11-01FDA Approved: VENLAFAXINE — Supplemental Application (Zydus Lifesciences Limited)
FDA granted supplemental approval for venlafaxine from Zydus Lifesciences Limited, signaling an approved modification to an existing generic…
-
CLINICAL_TRIALS trial_result · 2023-11-01Clinical Trial Update: Intravenous Ketamine Plus Neurocognitive Training for Depression [Phase 1, Phase 2]
A combined intravenous ketamine treatment with neurocognitive training for depression has completed Phase 1 and Phase 2 studies; results pos…
-
FDA approval · 2023-11-01FDA Approved: ARIPIPRAZOLE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic oral aripiprazole under an original ANDA.
-
FDA approval · 2023-10-30FDA Approved: CITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for citalopram hydrobromide from Aurobindo Pharma Limited.
-
FDA approval · 2023-10-23FDA Approved: BUPROPION HYDROCHLORIDE XL — Supplemental Application (Epic Pharma, LLC)
FDA approved a supplemental application for Bupropion hydrochloride extended-release (XL), manufactured by Epic Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2023-10-23Clinical Trial Update: Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression [Phase 4]
Phase 4 trial update assessing duloxetine in hospitalized patients with severe depression has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-10-19Clinical Trial Update: Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) [Phase 4]
Phase 4 trial assessing dopamine transporter occupancy of toludesvenlafaxine hydrochloride extended-release in patients with major depressiv…
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder [Phase 3]
Phase 3 trial evaluating brexpiprazole as maintenance treatment in adults with major depressive disorder has completed; results posted in 20…
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: Evaluating a Digital Peer Mentoring Platform With College Student Populations [NA]
A completed clinical trial evaluating a digital peer mentoring platform for college students focusing on well-being, psychological health, a…